{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:21:54Z","timestamp":1787016114743,"version":"build-2736575974"},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Investigation of the interference of mezagitamab in serological pre\u2010transfusion testing and the use of DaraEx to overcome it.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Administration of anti\u2010CD38 antibodies is a state\u2010of\u2010the\u2010art therapy for patients diagnosed with multiple myeloma. However, treatment with the currently approved anti\u2010CD38 antibodies regularly results in widespread agglutination of red blood cells in serological pre\u2010transfusion testing, making the determination of irregular antibodies and timely transfusion of compatible blood a challenge. Mezagitamab, a novel monoclonal anti\u2010CD38 antibody, is currently under clinical investigation, not only for the treatment of multiple myeloma but also for other indications such as generalised myasthenia gravis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods\/Materials<\/jats:title>\n                    <jats:p>Mezagitamab or daratumumab spiked plasmas, with or without irregular antibodies, were tested in column agglutination technique cards. DaraEx was used to mitigate occurring interferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mezagitamab interferes with the indirect antiglobulin test, with comparable titers but weaker reaction strengths than daratumumab. DaraEx, a reagent containing Fab fragments of an anti\u2010CD38 antibody, is able to completely overcome this interference in the antigen masking indirect antiglobulin test (AMIAT). DaraEx treatment does not interfere with tested irregular antibodies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>All novel anti\u2010CD38 antibodies, such as mezagitamab, have the potential to interfere in serological pre\u2010transfusion testing. While masking only one epitope, DaraEx has so far been an effective mitigation for all clinical anti\u2010CD38 antibodies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/tme.13139","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T22:30:56Z","timestamp":1744237856000},"page":"385-389","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antigen masking indirect antiglobulin test can mitigate the interference of Mezagitamab, a novel anti\u2010\n                    <scp>CD38<\/scp>\n                    antibody, in serological pre\u2010transfusion testing"],"prefix":"10.1111","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7022-0741","authenticated-orcid":false,"given":"Cora P.","family":"Habicht","sequence":"first","affiliation":[{"name":"Imusyn GmbH &amp; Co. KG  Hannover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Schneeweiss","sequence":"additional","affiliation":[{"name":"Imusyn GmbH &amp; Co. KG  Hannover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Takeda.A Study of TAK\u2010079 in People With Generalized Myasthenia Gravis. NCT04159805."},{"key":"e_1_2_10_3_1","unstructured":"Takeda.A Study of TAK\u2010079 in Adults With Persistent\/Chronic Primary Immune Thrombocytopenia. NCT04278924."},{"key":"e_1_2_10_4_1","unstructured":"Takeda.A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy. NCT05174221."},{"key":"e_1_2_10_5_1","unstructured":"Takeda (Millennium Pharmaceuticals Inc.).A Study to Investigate the Safety Tolerability Efficacy Pharmacokinetics and Immunogenicity of TAK\u2010079 Administered Subcutaneously as a Single Agent in Participants With Relapsed\/Refractory (r\/r) Multiple Myeloma (MM). NCT03439280."},{"key":"e_1_2_10_6_1","unstructured":"Takeda.A Study to Evaluate Subcutaneous TAK\u2010079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM). NCT03984097."},{"key":"e_1_2_10_7_1","unstructured":"Takeda (Millennium Pharmaceuticals Inc.).A Study to Evaluate the Safety Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK\u2010079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE). NCT03724916."},{"key":"e_1_2_10_8_1","unstructured":"European Medicines Agency.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/darzalex."},{"key":"e_1_2_10_9_1","unstructured":"European Medicines Agency.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sarclisa."},{"key":"e_1_2_10_10_1","unstructured":"Morphosys AG.https:\/\/www.morphosys.com\/en\/our-pipeline."},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02616"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17253"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13150"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13069"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17137"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000495773"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1804751"},{"key":"e_1_2_10_18_1","unstructured":"Imusyn.DaraEx Instructions for use. Version 22.www.imusyn.de\/IFU"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.13652"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.402"},{"key":"e_1_2_10_21_1","unstructured":"Grifols sCD38 Instructions for use. Version 3.0."}],"container-title":["Transfusion Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tme.13139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T05:37:53Z","timestamp":1755581873000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tme.13139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1111\/tme.13139"],"URL":"https:\/\/doi.org\/10.1111\/tme.13139","archive":["Portico"],"relation":{},"ISSN":["0958-7578","1365-3148"],"issn-type":[{"value":"0958-7578","type":"print"},{"value":"1365-3148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"2024-11-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}